Login  
Research Report
 
 
Home >> Country >> Malaysia >> Company
Latest Reports
Date Description Country Analyst Download
24-Sep-2021 Despite recent share price weakness, Dpharma, being the largest generic drug manufacturer with highest sales volume in Malaysia, remains fundamentally sound and provides a compelling Buy for investors. At 23.4x 2022 PER it is at a discount to its 5-year average PER of 32.9x Malaysia Malaysia Research Team
Copyright © 2013. Brought to you by PhillipCapital (India) Pvt. Ltd.      Designed and developed by C-MOTS Infotech (ISO 9001:2015 certified)